Please use this identifier to cite or link to this item:
|Title:||Effects of four antiplatelet/statin combined strategies on immune and inflammatory responses in patients with acute myocardial infarction undergoing pharmacoinvasive strategy: Design and rationale of the B and T Types of Lymphocytes Evaluation in Acute Myocardial Infarction (BATTLE-AMI) study: study protocol for a randomized controlled trial|
|Authors:||Fonseca, Francisco A. H. [UNIFESP]|
Izar, Maria Cristina [UNIFESP]
Maugeri, Ieda M. L. [UNIFESP]
Damiani, Lucas P.
Pinto, Ibraim M.
Szarf, Gilberto [UNIFESP]
Franca, Carolina N.
Bianco, Henrique T. [UNIFESP]
Moreira, Flavio T. [UNIFESP]
Caixeta, Adriano [UNIFESP]
Alves, Claudia M. R. [UNIFESP]
Lopes, Aline Soriano [UNIFESP]
Klassen, Aline [UNIFESP]
Tavares, Marina F. M.
Fonseca, Henrique A. [UNIFESP]
Carvalho, Antonio C. C. [UNIFESP]
|Publisher:||Biomed Central Ltd|
|Citation:||Trials. London, v. 18, p. -, 2017.|
|Abstract:||Background: Early reperfusion of the occluded coronary artery during acute myocardial infarction is considered crucial for reduction of infarcted mass and recovery of ventricular function. Effective microcirculation and the balance between protective and harmful lymphocytes may have roles in reperfusion injury and may affect final ventricular remodeling. Methods/design: BATTLE-AMI is an open-label, randomized trial comparing the effects of four therapeutic strategies (rosuvastatin/ticagrelor, rosuvastatin/clopidogrel, simvastatin plus ezetimibe/ticagrelor, or simvastatin plus ezetimibe/clopidogrel) on infarcted mass and left ventricular ejection fraction (LVEF) (blinded endpoints) in patients with ST-segment elevation myocardial infarction submitted to fibrinolytic therapy before coronary angiogram (pharmacoinvasive strategy). All patients (n = 300, 75 per arm) will be followed up for six months. The effects of treatment on subsets of B and T lymphocytes will be determined by flow-cytometry/ELISPOT and will be correlated with the infarcted mass, LVEF, and microcirculation perfusion obtained by cardiac magnetic resonance imaging. The primary hypothesis is that the combined rosuvastatin/ticagrelor therapy will be superior to other therapies (particularly for the comparison with simvastatin plus ezetimibe/clopidogrel) for the achievement of better LVEF at 30 days (primary endpoint) and smaller infarcted mass (secondary endpoint) at 30 days and six months. The trial will also evaluate the improvement in the immune/inflammatory responses mediated by B and T lymphocytes. Omics field (metabolomics and proteomics) will help to understand these responses by molecular events. Discussion: BATTLE-AMI is aimed to (1) evaluate the role of subsets of lymphocytes on microcirculation improvement and (2) show how the choice of statin/antiplatelet therapy may affect cardiac remodeling after acute myocardial infarction with ST elevation.|
|Appears in Collections:||Artigo|
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.